Prediction of Cognitive Conversion Within the Alzheimer's Disease Continuum Using Deep Learning

Overview

Journal Alzheimers Res Ther

Date 2025 Feb 13

PMID 39948600

Authors

Siyu Yang

Xintong Zhang

Xinyu Du

Peng Yan

Jing Zhang

Wei Wang

Jing Wang

Lei Zhang

Huaiqing Sun

Yin Liu

Xinran Xu

Yaxuan Di

Jin Zhong

Caiyun Wu

Jan D Reinhardt

Yu Zheng

Ting Wu

Affiliations

Soon will be listed here.

Abstract

Background: Early diagnosis and accurate prognosis of cognitive decline in Alzheimer's disease (AD) is important to timely assignment to optimal treatment modes. We aimed to develop a deep learning model to predict cognitive conversion to guide re-assignment decisions to more intensive therapies where needed.

Methods: Longitudinal data including five variable sets, i.e. demographics, medical history, neuropsychological outcomes, laboratory and neuroimaging results, from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort were analyzed. We first developed a deep learning model to predicted cognitive conversion using all five variable sets. We then gradually removed variable sets to obtained parsimonious models for four different years of forecasting after baseline within acceptable frames of reduction in overall model fit (AUC remaining > 0.8).

Results: A total of 607 individuals were included at baseline, of whom 538 participants were followed up at 12 months, 482 at 24 months, 268 at 36 months and 280 at 48 months. Predictive performance was excellent with AUCs ranging from 0.87 to 0.92 when all variable sets were considered. Parsimonious prediction models that still had a good performance with AUC 0.80-0.84 were established, each only including two variable sets. Neuropsychological outcomes were included in all parsimonious models. In addition, biomarker was included at year 1 and year 2, imaging data at year 3 and demographics at year 4. Under our pre-set threshold, the rate of upgrade to more intensive therapies according to predicted cognitive conversion was always higher than according to actual cognitive conversion so as to decrease the false positive rate, indicating the proportion of patients who would have missed upgraded treatment based on prognostic models although they actually needed it.

Conclusions: Neurophysiological tests combined with other indicator sets that vary along the AD continuum can improve can provide aid for clinical treatment decisions leading to improved management of the disease.

Trail Registration Information: ClinicalTrials.gov Identifier: NCT00106899 (Registration Date: 31 March 2005).

References

Salehipour A, Bagheri M, Sabahi M, Dolatshahi M, Boche D . Combination Therapy in Alzheimer's Disease: Is It Time?. J Alzheimers Dis. 2022; 87(4):1433-1449. DOI: 10.3233/JAD-215680. View

Hughes C, Berg L, Danziger W, COBEN L, Martin R . A new clinical scale for the staging of dementia. Br J Psychiatry. 1982; 140:566-72. DOI: 10.1192/bjp.140.6.566. View

Shadbahr T, Roberts M, Stanczuk J, Gilbey J, Teare P, Dittmer S . The impact of imputation quality on machine learning classifiers for datasets with missing values. Commun Med (Lond). 2023; 3(1):139. PMC: 10558448. DOI: 10.1038/s43856-023-00356-z. View

Brickman A, Manly J, Honig L, Sanchez D, Reyes-Dumeyer D, Lantigua R . Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. Alzheimers Dement. 2021; 17(8):1353-1364. PMC: 8451860. DOI: 10.1002/alz.12301. View

Nasreddine Z, Phillips N, Bedirian V, Charbonneau S, Whitehead V, Collin I . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005; 53(4):695-9. DOI: 10.1111/j.1532-5415.2005.53221.x. View

Qiu S, Joshi P, Miller M, Xue C, Zhou X, Karjadi C . Development and validation of an interpretable deep learning framework for Alzheimer's disease classification. Brain. 2020; 143(6):1920-1933. PMC: 7296847. DOI: 10.1093/brain/awaa137. View

Cummings J, Tong G, Ballard C . Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. J Alzheimers Dis. 2019; 67(3):779-794. PMC: 6398562. DOI: 10.3233/JAD-180766. View

Qaseem A, Snow V, Cross Jr J, Forciea M, Hopkins Jr R, Shekelle P . Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008; 148(5):370-8. DOI: 10.7326/0003-4819-148-5-200803040-00008. View

Soldan A, Pettigrew C, Fagan A, Schindler S, Moghekar A, Fowler C . ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes. Neurology. 2019; 92(14):e1567-e1579. PMC: 6448449. DOI: 10.1212/WNL.0000000000007248. View

10.

Shen X, Li J, Wang H, Li H, Huang Y, Yang Y . Plasma amyloid, tau, and neurodegeneration biomarker profiles predict Alzheimer's disease pathology and clinical progression in older adults without dementia. Alzheimers Dement (Amst). 2020; 12(1):e12104. PMC: 7513626. DOI: 10.1002/dad2.12104. View

11.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

12.

Llinas-Regla J, Vilalta-Franch J, Lopez-Pousa S, Calvo-Perxas L, Torrents Rodas D, Garre-Olmo J . The Trail Making Test. Assessment. 2015; 24(2):183-196. DOI: 10.1177/1073191115602552. View

13.

Chatterjee P, Pedrini S, Ashton N, Tegg M, Goozee K, Singh A . Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimers Dement. 2021; 18(6):1141-1154. DOI: 10.1002/alz.12447. View

14.

James C, Ranson J, Everson R, Llewellyn D . Performance of Machine Learning Algorithms for Predicting Progression to Dementia in Memory Clinic Patients. JAMA Netw Open. 2021; 4(12):e2136553. PMC: 8678688. DOI: 10.1001/jamanetworkopen.2021.36553. View

15.

Jia X, Wang Z, Huang F, Su C, Du W, Jiang H . A comparison of the Mini-Mental State Examination (MMSE) with the Montreal Cognitive Assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population: a cross-sectional study. BMC Psychiatry. 2021; 21(1):485. PMC: 8489046. DOI: 10.1186/s12888-021-03495-6. View

16.

Grossberg G, Tong G, Burke A, Tariot P . Present Algorithms and Future Treatments for Alzheimer's Disease. J Alzheimers Dis. 2019; 67(4):1157-1171. PMC: 6484274. DOI: 10.3233/JAD-180903. View

17.

Moroney J, Bagiella E, Desmond D, Hachinski V, Molsa P, Gustafson L . Meta-analysis of the Hachinski Ischemic Score in pathologically verified dementias. Neurology. 1997; 49(4):1096-105. DOI: 10.1212/wnl.49.4.1096. View

18.

Smarr K, Keefer A . Measures of depression and depressive symptoms: Beck Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scale (HADS), and Patient Health.... Arthritis Care Res (Hoboken). 2012; 63 Suppl 11:S454-66. DOI: 10.1002/acr.20556. View

19.

Malloy P, Cummings J, Coffey C, Duffy J, Fink M, Lauterbach E . Cognitive screening instruments in neuropsychiatry: a report of the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci. 1997; 9(2):189-97. DOI: 10.1176/jnp.9.2.189. View

20.

Chatterjee P, Pedrini S, Doecke J, Thota R, Villemagne V, Dore V . Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement. 2022; 19(4):1117-1134. DOI: 10.1002/alz.12724. View